Upon antigen recognition, naive T cells undergo rapid expansion and activation. The energy
requirements for this expansion are formidable, and T‐cell activation is accompanied by …

During the past 6 years, there have been substantial advances in our understanding of
human immunodeficiency virus 1 and other viruses, such as hepatitis B virus and hepatitis C …

Peripheral T cell populations are maintained by production of naive T cells in the thymus,
clonal expansion of activated cells, cellular self-renewal (or homeostatic proliferation), and …

Tisagenlecleucel is a chimeric antigen receptor–T cell therapy that facilitates the killing of
CD19+ B cells. A model was developed for the kinetics of tisagenlecleucel and the impact of …

We fit a mathematical model to data characterizing the primary cellular immune response to
lymphocytic choriomeningitis virus. The data enumerate the specific CD8+ T cell response to …

Although potent combination therapy is usually able to suppress plasma viral loads in HIV-1
patients to below the detection limit of conventional clinical assays, a low level of viremia …

HIV-1 eradication from infected individuals has not been achieved with the prolonged use of
highly active antiretroviral therapy (HAART). The cellular reservoir for HIV-1 in resting …

Mathematical models have been used to understand the factors that govern infectious
disease progression in viral infections. Here we focus on hepatitis B virus (HBV) dynamics …

The cellular immune response to primary influenza virus infection is complex, involving
multiple cell types and anatomical compartments, and is difficult to measure directly. Here …

Chimeric antigen receptor (CAR)‐T cell therapy has achieved considerable success in
treating B‐cell hematologic malignancies. However, the challenges of extending CAR‐T …